Sandoz Forms Insulin Biosimilars Deal With Gan & Lee
In line with its strategy to expand its biosimilars business, Sandoz has entered into an agreement with China’s Gan & Lee to market and supply three insulin biosimilars in the EU, US, and other key territories.
You may also be interested in...
Sandoz’ partnership with China’s Gan & Lee covering three biosimilar insulin products continues to make progress, with the conclusion of a pair of Phase III trials involving a proposed biosimilar to Lantus (insulin glargine).
Celebrating a “major milestone in the biosimilar clinical development programs,” Gan & Lee has just presented positive data at the recent at the Scientific Sessions of the American Diabetes Association.
Sandoz is benefiting from its focus on a “pure play” generics and biosimilars model that is unique among its peers, CEO Richard Saynor tells Generics Bulletin in an exclusive interview.